Detalhe da pesquisa
1.
Pathophysiologic implications of elevated prevalence of hereditary alpha-tryptasemia in all mastocytosis subtypes.
J Allergy Clin Immunol
; 153(1): 349-353.e4, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37633651
2.
Histological characterization of liver involvement in systemic mastocytosis.
Liver Int
; 2024 Mar 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554045
3.
Efficacy and safety of mammalian target of rapamycin inhibitors in systemic mastocytosis: A nationwide French pilot study.
Am J Hematol
; 99(6): 1095-1102, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38581211
4.
A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure.
Haematologica
; 104(8): 1565-1571, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30733271
5.
Comment on: Hematological malignancies in giant cell arteritis: a French population-based study.
Rheumatology (Oxford)
; 60(11): e425-e426, 2021 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33993213
6.
Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup.
Blood
; 124(8): 1312-9, 2014 Aug 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25006122
7.
Anti-apoptotic role and clinical relevance of neurotrophins in diffuse large B-cell lymphomas.
Br J Cancer
; 113(6): 934-44, 2015 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26284337
8.
Multicentric study underlining the interest of adding CD5, CD7 and CD56 expression assessment to the flow cytometric Ogata score in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms.
Haematologica
; 100(4): 472-8, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637056
9.
Factors associated with the designation of a health care proxy and writing advance directives for patients suffering from haematological malignancies.
BMC Palliat Care
; 13: 57, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25859160
10.
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study.
Lancet Haematol
; 10(7): e521-e529, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37245522
11.
Reduced peripheral blood dendritic cell and monocyte subsets in MDS patients with systemic inflammatory or dysimmune diseases.
Clin Exp Med
; 23(3): 803-813, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-35953763
12.
Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.
Leukemia
; 36(10): 2519-2527, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36071100
13.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Clin Cancer Res
; 28(23): 5211-5220, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36201165
14.
Effective Anti-SARS-CoV-2 Immune Response in Patients With Clonal Mast Cell Disorders.
J Allergy Clin Immunol Pract
; 10(5): 1356-1364.e2, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35074600
15.
c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study.
Front Oncol
; 11: 638897, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33959502
16.
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Blood
; 122(13): 2286-8, 2013 Sep 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24072851
17.
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Haematologica
; 95(6): 892-9, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20015890
18.
How should we diagnose and treat blastic plasmacytoid dendritic cell neoplasm patients?
Blood Adv
; 3(24): 4238-4251, 2019 12 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31869411
19.
Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients.
Br J Haematol
; 162(3): 413-5, 2013 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-23656172
20.
A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML.
Leukemia
; 36(11): 2739-2742, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36104395